Parimifasor( LYC-30937-EC | LYC30937 )

Catalog No. M12714 CAS No. 1796641-10-5

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

Parimifasor
Note

Research use only, not for human use.
Brief Description

Parimifasor(LYC-30937-EC, LYC30937) is an orally bioavailable, enteric-coated ATPase modulator as a gut-directed therapy for the treatment of inflammatory bowel disease (IBD).
Description

Parimifasor(LYC-30937-EC, LYC30937) is an orally bioavailable, enteric-coated ATPase modulator as a gut-directed therapy for the treatment of inflammatory bowel disease (IBD).Psoriasis Phase 2 Clinical.
In Vitro

——
In Vivo

——
Synonyms

LYC-30937-EC | LYC30937
Pathway

Others
Target

Other Targets
Recptor

Others
Research Area

Inflammation/Immunology
Indication

Psoriasis

CAS Number

1796641-10-5
Formula Weight

460.214
Molecular Formula

C18H11Cl2F4N5O
Purity

>98% (HPLC)
Solubility

DMSO: ≥150 mg/mL （ < 1 mg/ml refers to the product slightly soluble or insoluble )
SMILES

O=C(/N=C(NC1=CC(F)=CC(Cl)=C1)\NC2=NNC(C(F)(F)F)=C2)C3=CC=CC(Cl)=C3
Chemical Name

3-chloro-N-[(3-chloro-5-fluoroanilino){[5-(trifluoromethyl)-1H-pyrazol-3-yl]amino}methylidene]benzamide